Actavis (ACT) Updates on Key Pipeline Program, Potential Market Opportunities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Actavis (ACT) PT Lifted to $340 at Argus
February 20, 2015 9:32 AM ESTArgus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock... More
Actavis (ACT) PT Lifted to $345 at Guggenheim Following Q4 Results and Update
February 18, 2015 4:23 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from $300.00) following Q4 results and outlook.
Chen comments, "We are raising our PT to $345 from $300 post a 4Q14 beat and strong outlook for '15. We use a... More
Actavis (ACT) to Adopt 'Allergan' Name
February 18, 2015 7:04 AM ESTActavis plc (NYSE: ACT) today announced that it will adopt a new corporate name Allergan following the anticipated successful completion of the acquisition of Allergan, Inc (NYSE: AGN). The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its Annual General Meeting later this year.
"The pending... More
Actavis (ACT) Reports In-Line Q4 EPS; Guides FY15 EPS, Revs
February 18, 2015 6:32 AM ESTActavis (NYSE: ACT) reported Q4 EPS of $3.91, in-line with the analyst estimate of $3.91. Revenue for the quarter came in at $4.01 billion versus the consensus estimate of $3.84 billion.
Actavis sees FY2015 EPS of $16.30-$17.30, versus the consensus of $16.63. Actavis sees FY2015 revenue of $15.0 billion,... More
